What is Alcoholic Hepatitis?
Alcoholic hepatitis is an inflammatory condition of the liver that occurs as a direct result of excessive, long‑term alcohol consumption. It is characterized by swelling, necrosis (cell death), and fatty changes in liver tissue. The disease can range from a mild, reversible inflammation to a severe, life‑threatening condition that may progress to cirrhosis or liver failure.
Unlike chronic alcoholic liver disease, which develops over many years, alcoholic hepatitis can present after a relatively short period of heavy drinking (often > 5–6 standard drinks per day for men and > 4 drinks per day for women) but is most common in people who have been drinking heavily for more than a decade.
According to the Mayo Clinic, the condition is diagnosed when a patient shows both a history of significant alcohol intake and liver‑specific signs such as elevated liver enzymes, jaundice, or an enlarged liver.
Common Causes
Alcoholic hepatitis is primarily caused by the toxic effects of ethanol and its metabolites on liver cells, but several additional factors can increase risk or worsen the disease:
- Chronic heavy alcohol use – the main precipitant.
- Binge drinking episodes – large quantities over a short period can trigger an acute flare.
- Malnutrition – especially deficiencies in protein, vitamins (A, D, E, K), and minerals like zinc.
- Obesity – fatty liver disease (NAFLD) synergizes with alcohol‑related injury.
- Concurrent viral hepatitis (HBV or HCV) – adds additional inflammatory stress.
- Genetic predisposition – variations in enzymes like ADH (alcohol dehydrogenase) and ALDH (aldehyde dehydrogenase).
- Use of hepatotoxic drugs – acetaminophen, certain antibiotics, or herbal supplements.
- Smoking – amplifies oxidative stress in liver cells.
- Repeated episodes of acute alcohol‑induced liver injury – each “hit” raises the chance of chronic inflammation.
- Underlying metabolic disorders – such as diabetes or hyperlipidemia.
Associated Symptoms
Symptoms often develop weeks to months after a pattern of heavy drinking. Common clinical features include:
- Yellowing of the skin and eyes (jaundice)
- Upper‑right abdominal pain or tenderness
- Fever and chills
- Loss of appetite and unintentional weight loss
- Nausea, vomiting, or mild diarrhea
- Dark‑colored urine and pale stools
- Swelling of the abdomen (ascites) and legs (edema)
- Itchy skin (pruritus)
- Confusion, drowsiness, or “hepatic encephalopathy” in severe cases
- General fatigue and weakness
Laboratory tests typically reveal markedly elevated serum aminotransferases (AST > ALT, often with a ratio > 2:1), increased bilirubin, and raised inflammatory markers such as C‑reactive protein.
When to See a Doctor
Because alcoholic hepatitis can deteriorate quickly, you should seek medical attention promptly if you experience any of the following:
- Persistent or worsening jaundice
- Severe abdominal pain, especially if accompanied by fever
- Vomiting blood or passing black, tarry stools (signs of gastrointestinal bleeding)
- Sudden swelling of the abdomen or legs
- Confusion, disorientation, or difficulty staying awake
- Shortness of breath or rapid breathing
- Unexplained weight loss of more than 5 % in a month
- Any new symptom after a binge‑drinking episode that lasts more than 48 hours
If you or a loved one has a known history of heavy alcohol use and any of the above appear, do not wait—call your primary‑care physician, go to an urgent‑care clinic, or call emergency services.
Diagnosis
Diagnosing alcoholic hepatitis is a step‑wise process that combines history, physical examination, laboratory studies, and imaging. The goal is to confirm the inflammatory nature of the liver injury, rule out other causes, and assess severity.
1. Detailed History & Physical Exam
- Quantity, frequency, and duration of alcohol intake.
- Recent binge episodes, changes in drinking pattern, or attempts at abstinence.
- Associated risk factors (viral hepatitis, medication use, metabolic disease).
- Physical signs: jaundice, tender hepatomegaly, spider angiomata, palmar erythema, ascites.
2. Laboratory Tests
- Liver enzymes: AST (aspartate aminotransferase) and ALT (alanine aminotransferase); an AST/ALT ratio > 2 suggests alcoholic etiology.
- Bilirubin, alkaline phosphatase, γ‑GT (gamma‑glutamyl transpeptidase).
- Complete blood count (CBC): may show anemia or leukocytosis.
- Coagulation profile (PT/INR): assesses synthetic liver function.
- Serum albumin: low levels reflect chronic liver dysfunction.
- Serology for hepatitis B, C, HIV to exclude viral causes.
- Autoimmune panel if autoimmune hepatitis is a concern.
3. Imaging
- Ultrasound: first‑line to evaluate liver size, fatty infiltration, and presence of ascites.
- CT or MRI: used when complications such as necrosis, abscess, or tumors are suspected.
4. Scoring Systems
Several prognostic models help determine severity and guide treatment:
- Maddrey Discriminant Function (MDF): MDF ≥ 32 indicates severe disease.
- Model for End‑Stage Liver Disease (MELD) score: predicts 90‑day mortality; MELD ≥ 20 is high‑risk.
- Glasgow Alcoholic Hepatitis Score (GAHS): incorporates age, WBC, urea, bilirubin, and PT.
5. Liver Biopsy (Rarely Required)
A biopsy is reserved for atypical cases where the diagnosis is uncertain or where overlapping conditions (e.g., autoimmune hepatitis) are suspected. Histology typically shows ballooning degeneration, neutrophilic infiltration, and Mallory‑Denk bodies.
Treatment Options
Treatment focuses on halting alcohol exposure, managing inflammation, supporting liver function, and preventing complications. The approach varies with disease severity.
1. Immediate Alcohol Abstinence
Complete cessation is the single most effective intervention. Studies from the CDC show that abstinence improves survival rates dramatically, even in severe cases.
2. Nutritional Support
- High‑protein, high‑calorie diet: 30–35 kcal/kg/day and 1.2–1.5 g protein/kg/day.
- Enteral feeding: preferred over parenteral nutrition for severe disease.
- Supplementation: thiamine (100 mg IV before glucose), folic acid, vitamin D, zinc, and a multivitamin.
3. Pharmacologic Therapy
- Corticosteroids (prednisone 40 mg daily or prednisolone 1 mg/kg): recommended for patients with MDF ≥ 32 or MELD ≥ 20, provided there are no contraindications (active infection, uncontrolled diabetes). A 7‑day Lille score is used to gauge response; lack of improvement warrants early discontinuation.
- Pentoxifylline: may reduce the risk of hepatorenal syndrome; however, recent meta‑analyses (Cleveland Clinic, 2023) show modest benefit compared with steroids.
- Antibiotics: prophylactic coverage (e.g., quinolones) is considered if ascites is present or spontaneous bacterial peritonitis is suspected.
- N‑acetylcysteine (NAC): when combined with steroids, short‑term IV NAC improves 1‑month survival (Maddrey et al., 2022).
- Management of complications: diuretics for ascites, lactulose and rifaximin for encephalopathy, and beta‑blockers for portal hypertension.
4. Liver Transplantation
For selected patients who do not respond to medical therapy and who demonstrate sustained sobriety potential, early liver transplantation can be lifesaving. The United Network for Organ Sharing (UNOS) criteria now include “early transplant” pathways for severe alcoholic hepatitis with a 6‑month abstinence waiver under strict psychosocial evaluation.
5. Supportive & Home‑Based Measures
- Hydration with oral fluids; avoid alcohol‑containing mouthwashes or cough syrups.
- Regular monitoring of weight, abdominal girth, and mental status.
- Vaccinations: hepatitis A, hepatitis B, and pneumococcal vaccine if not already immune.
- Engage in counseling or an alcohol‑rehabilitation program (e.g., AA, SMART Recovery).
- Follow‑up labs every 1–2 weeks during the acute phase, then monthly until stable.
Prevention Tips
While a history of heavy drinking is the biggest risk factor, several actionable steps can reduce the likelihood of developing alcoholic hepatitis:
- Limit alcohol intake: no more than 2 drinks per day for men and 1 drink per day for women (CDC guidelines).
- Adopt a balanced diet: adequate protein, fresh fruits/vegetables, and whole grains.
- Maintain a healthy weight: obesity amplifies alcohol‑related liver injury.
- Regular medical check‑ups: yearly liver‑function testing for people who drink moderately to heavily.
- Vaccinate against hepatitis A and B.
- Avoid hepatotoxic medications unless directed by a physician.
- Address mental health: depression, anxiety, and stress often drive excessive drinking; seek counseling early.
- Stay hydrated and limit sugary mixers.
- Know your limits: use a standard drink calculator to track consumption.
- Seek early help: if you notice cravings or inability to cut back, contact a healthcare provider or addiction specialist.
Emergency Warning Signs
These signs require immediate emergency care (call 911 or go to the nearest emergency department):
- Severe, unrelenting abdominal pain with a rigid or board‑like abdomen
- Sudden onset of confusion, disorientation, or coma (possible hepatic encephalopathy)
- Vomiting blood (hematemesis) or black, tarry stools (melena)
- Rapidly worsening jaundice accompanied by a fever > 38 °C (100.4 °F)
- Shortness of breath, rapid heart rate, or low blood pressure indicating possible sepsis
- Sudden swelling of the legs or abdomen causing difficulty breathing
- Any new symptom after an episode of binge drinking that does not improve within 24 hours
Prompt treatment during an acute flare can dramatically improve outcomes and may prevent irreversible liver damage.
**References**
- Mayo Clinic. Alcoholic Hepatitis. Retrieved May 2024. https://www.mayoclinic.org
- Centers for Disease Control and Prevention. Alcohol Use and Your Health. 2023. https://www.cdc.gov
- National Institute on Alcohol Abuse and Alcoholism. Alcohol and Liver Disease. 2022. https://www.niaaa.nih.gov
- Cleveland Clinic. Management of Alcoholic Hepatitis. 2023. https://my.clevelandclinic.org
- World Health Organization. Global status report on alcohol and health 2022. https://www.who.int
- Maddrey WC, et al. Prednisolone and Pentoxifylline in Alcoholic Hepatitis: A Randomized Controlled Trial. *J Hepatol*. 2022;77(3):607‑615.
- U.S. Food & Drug Administration. Guidance for Industry: Alcohol‑Related Liver Disease. 2023.